Speaker Interview >
Marken
Sr. Director, Business Development
What type of benefits can Direct-toPatient (DTP) delivery have on MultiCountry Trials?
DTP delivery of clinical trial materials
can facilitate access to a larger patient
population and reduce the burden of
long distance travel for those with late
stage cancer or other debilitating conditions. The expanding global
market for orphan drugs is particularly suited for DTP solutions,
because of the greater geographical distribution of a smaller
number of patients and the prevalence of biotechnology derived
treatment options that may require more sophisticated handling
during transit. In all areas of the world, Marken’s DTP delivery
services make participation in clinical trials easier for the patient,
which can improve enrollment, compliance and patient retention.
Are there regulatory challenges specific to using DTP for clinical
trials?
21
There are regulatory challenges, but DTP delivery of IMP is now
being performed by Marken in many countries worldwide, and the
regulatory climate is changing as more protocols are being reviewed
by local authorities. Having established relationships in over 40
co